Menlo Park, United States
Refuge Biotechnologies, founded in 2015, is at the forefront of the Biotechnology sector with a focused mission—DESIGNING INTELLIGENT CELL THERAPIES TO FIGHT CANCER. Based in the United States, the company engineers advanced cancer immunotherapy solutions by tapping into synthetic biology and gene engineering.
Their unique approach involves creating cell therapies that can adapt to their environment, activating or suppressing multiple genes at once, thus offering more efficacious and targeted cancer treatments compared to traditional methods. This innovative strategy holds significant promise for the future of Health Care and Health and Wellness.
In terms of financial positioning, the last substantial influx of capital was a $25.00M Series B investment on 02 May 2018. The round was backed by prominent investors like DHVC, WuXi Healthcare Ventures, and Sequoia Capital China, highlighting strong confidence from well-respected industry players.
